Smiths Detection equips Leonardo di Vinci International Airport in Rome with advanced carry-on baggage screening technology
14.9.2022 16:03:00 EEST | Business Wire | Press release
Smiths Detection, a global leader in threat detection and security inspection technologies, announces that it has begun installing 30 HI-SCAN 6040 CTiX carry-on baggage screening systems at Leonardo di Vinci International Airport in Rome. The installation of this world-leading technology reflects the airport’s high standards for passenger service excellence and process automation, having recently been awarded the ACI Best Airport in Europe for the fourth time in the last five years.
Smiths Detection’s HI-SCAN 6040 CTiX is a computed tomography (CT) X-ray scanner producing high-resolution volumetric 3D images for quicker and deeper baggage assessment and low false-alarm rates. The scanners allow for electronics and liquids to remain in bags, speeding up passenger screening and reducing touchpoints.
The combination of the CT X-ray scanners, alongside 45 already supplied Smiths Detection IONSCAN 600 trace detectors, will further improve security and operational efficiency. The IONSCAN 600 is a highly sensitive, non-radioactive, lightweight, portable desktop system that detects and identifies trace amounts of explosives and narcotics.
The HI-SCAN 6040 CTiX can be equipped with Smiths Detection’s object recognition software, iCMORE, which uses advanced algorithms to reduce the burden on operators – and potential errors – by automating the detection process for prohibited items.
Stefano Scardigli, Senior Key Account, Smiths Detection said: “We are delighted to supply Leonardo di Vinci Rome International Airport with 30 HI-SCAN 6040 CTiX scanners. Utilising 3D imagery, our scanners offer the advanced screening of carry-on baggage, enhancing security and improving operational efficiency. Being able to leave electronics and liquids in carry-on baggage will help expedite the screening process, especially in light of the well documented staffing pressures at airports around the world.”
Marco Stramaccioni, Chief Executive Officer of ADR Security for Leonardo da Vinci Rome International Airport said: “Aeroporti di Roma looks forward to be a frontrunner for passenger experience and security at Leonardo di Vinci Rome International Airport. As passenger numbers increase, we will be well placed to efficiently screen passengers, reducing the burden on our operators. By harnessing the power of CT technology, we have futureproofed our security checkpoints.”
Smiths Detection’s HI-SCAN 6040 CTiX is certified by the U.S. Transportation Security Administration (TSA) under the Accessible Property Screening System (APSS) program to detection standard 6.2, Level 1, permitting the scanner to operate at an enhanced level with lower false alarm rates, as well as ECAC and STAC EDS CB C3 approval.
###
About the Products
- HI-SCAN 6040 CTiX: https://www.smithsdetection.com/products/hi-scan-6040-ctix/
- IONSCAN 600: https://www.smithsdetection.com/products/ionscan-600/
- iCMORE: https://www.smithsdetection.com/products/icmore/
About Smiths Detection
Smiths Detection, a division of Smiths Group, is a global leader in inspection and detection technologies for the air transport, ports and borders, armed forces and urban security markets. With more than 70 years of experience in the field, we offer the necessary solutions to protect society from the threats posed by explosives, prohibited weapons, contraband, toxic chemical agents and narcotics.
Our mission is simple: to ensure the security, peace of mind and freedom of movement on which the world depends.
Please visit http://www.smithsdetection.com/ for further information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005455/en/
Contact information
FTI Consulting:
Tom Hufton/Georgina Reeves/Zoe Williams
sc.smithsdetection@fticonsulting.com
+44 (0)20 3727 1000
Smiths Detection:
Sophie Mills, Head of Corporate Communications
sophie.mills@smithsdetection.com
+44 (0)73 8423 6474
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom